Startup · $15m raised
Melbourne
Every investor coverage indicates participated in a round Chemgenex raised.
Companies Chemgenex acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Adam R. Craig | Senior Vice President and Chief Medical Officer | GBS Ventures (Tue 2 Jun 2009), GBS Ventures (Mon 8 Oct 2007) |
| Dr Greg Collier | Managing Director and Chief Executive Officer (former) | GBS Ventures (Tue 29 Mar 2011), GBS Ventures (Tue 2 Nov 2010), GBS Ventures (Fri 22 Oct 2010), GBS Ventures (Wed 28 Oct 2009), GBS Ventures (Mon 20 Jul 2009), GBS Ventures (Mon 29 Jun 2009), GBS Ventures (Tue 9 Jun 2009), GBS Ventures (Tue 2 Jun 2009), GBS Ventures (Mon 8 Oct 2007), GBS Ventures (Thu 31 May 2007), GBS Ventures (Wed 4 Apr 2007), GBS Ventures (Tue 3 Apr 2007) |
| Dr Julie Cherrington | Director (former) | GBS Ventures (Tue 11 Aug 2009), GBS Ventures (Mon 29 Jun 2009) |
Stories naming Chemgenex. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
Australian diabetes biotech Verva sold all its IP to two biotechs and entered liquidation with PKF Australia appointed; background recalls early Adipogen backing from Uniseed, QIC BioVentures and GBS Ventures.
ChemGenex has signed a convertible note deal giving Cephalon up to A$15 million in notes, plus options over 19.9 percent of shares held by Stragen and Merck; major shareholders back the issue.
Also GBS Ventures
AusBiotech's release announces ChemGenex chief executive Greg Collier won the 2009 Chairman's Excellence Award for his contribution to Australian biotechnology, noting the company's US drug application for a leukemia medicine.
Xenome appointed Dr Julie Cherrington, president of San Diego biopharmaceutical Phenomix and a Progen board member, as an independent director of the drug developer, effective 1 August 2009.
ChemGenex Pharmaceuticals has hired Thomas DeZao as senior vice president and chief commercial officer to lead US commercialisation of its leukemia drug omacetaxine; his past roles span Genitope, Corixa/Coulter, Asta Medica and Chiron.
ASX-listed drug developer ChemGenex will quit NASDAQ and SEC reporting to cut compliance costs, and three directors step down in July while staying on as advisers.
ChemGenex Pharmaceuticals reports pre-clinical findings that omacetaxine destroys leukemic stem cells in chronic myeloid leukemia models, presented at the European Hematology Association congress, with collaborators in Glasgow and a US leukemia specialist.
ChemGenex reported Phase 2/3 trial results for omacetaxine in resistant CML patients at ASCO, with investigators suggesting it could become the first workable therapy for T315I-mutant patients; regulatory filing targeted for Q3.
ChemGenex Pharmaceuticals has hired oncology drug developer Dr Adam Craig as its chief medical officer, its third senior clinical appointment lately, as it prepares its cancer drug omacetaxine for a regulatory filing.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.
ChemGenex has begun enrolling patients in a second phase 2/3 trial testing Ceflatonin in chronic myeloid leukemia patients resistant to prior tyrosine kinase inhibitor treatment, with data expected in 2008.
ChemGenex completed an A$10.5m rights issue following an equal February institutional placement, a combined A$21m raise, with Alta Partners and GBS Venture Partners increasing their stakes to fund Ceflatonin leukemia trials.